The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis

Cairo University25 enrolled

Overview

Psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. Several cytokines have been found to be involved in the complex pathogenesis of this disease. Il- 36 is one of the cytokines sharing in psoriasis pathogenesis, as its levels are elevated in psoriatic plaques. Cathepsin G is known to activate Il- 36 and promote inflammation in psoriasis.NB-UVB is one of the important treatment modalities for psoriasis. The aim of this study is to detect the effect of NB-UVB on the lesional levels of IL-36 in psoriasis.

25 psoriasis patients will receive 26 sessions of phototherapy (NB-UVB). Patients will receive 3 sessions per week. Tissue levels of IL-36 and Cathepsin G will be assessed in skin lesions before starting treatment and after completing the 26 sessions.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Psoriasis

Interventions

NB-UVBDEVICE

Phototherapy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with psoriasis vulgaris of both sexes * Age between 18 and 60 years old. Exclusion Criteria: * Pregnant females * Patients receiving systemic treatment or topical treatment for psoriasis within the past two months. * Patients having other dermatological diseases.

Outcomes

Primary Outcomes

changes in Il-36 levels in 25 psoriasis patients after 26 sessions of NB-UVB

primary

Time frame: 6 months

Secondary Outcomes

changes in cathepsin G levels in 25 psoriasis patients after 26 sessions of NB-UVB psoriasis

secondary

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.